Cybersecurity keeps sinking FDA submissions, and that should worry every medtech AI team
A cybersecurity executive argues that security failures are now a leading reason FDA medical device submissions get rejected. The warning is especially relevant for AI products, where data flows, connected systems, and software updates widen the attack surface.
The claim that cybersecurity is a top reason the FDA rejects submissions should be read as more than a compliance anecdote. It reflects the reality that connected medical technology is now inseparable from digital risk, and AI tools often magnify that exposure by depending on continuous data exchange, cloud infrastructure, and iterative updates.
For developers, this means security can no longer be treated as an engineering afterthought. If a device’s AI performance depends on data integrity, then cybersecurity becomes part of the clinical claim itself. A compromised system is not just a technical defect; it can become a patient-safety issue.
The FDA’s apparent emphasis here also suggests that regulators are linking software quality and threat modeling more tightly than many firms expected. That is a problem for teams that see security as a checkbox, but an opportunity for companies willing to build defensible architectures from the start.
In practical terms, the message is simple: an AI product that cannot prove it is secure may never get the chance to prove it is effective. As medtech becomes more networked, the burden of trust shifts from the model alone to the entire system around it.